Crosstalk between peroxisome proliferator-activated receptor-γ and angiotensin II in renal tubular epithelial cells in IgA nephropathy

Clinical Immunology

Volumn 132, Issue 2, 2009, Pages 266-276

  Xiao, Jing ^a   Leung, Joseph C K ^a   Chan, Loretta Y Y ^a   Tang, Sydney C W ^a   Lai, Kar Neng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiotensin II; Angiotensin II type 1 receptor; Peroxisome proliferator activated receptor ; Tubulointerstitial injury

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BETA ARRESTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY TUBULE EPITHELIUM; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANILIDES; BLOTTING, WESTERN; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOGLOBULIN A; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; KIDNEY TUBULES; LOSARTAN; MALE; MESANGIAL CELLS; NF-KAPPA B; PPAR GAMMA; RECEPTOR CROSS-TALK; RECEPTOR, ANGIOTENSIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 67649964290     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2009.04.004     Document Type: Article

References (43)

1. Barratt J., and Feehally J. IgA nephropathy. J. Am. Soc. Nephrol. 16 (2005) 2088-2097
2. Myllymaki J.M., Honkanen T.T., Syrjanen J.T., Helin H.J., Rantala I.S., Pasternack A.I., and Mustonen J.T. Severity of tubulointerstitial inflammation and prognosis in immunoglobulin A nephropathy. Kidney Int. 71 (2007) 343-348
3. Chan L.Y., Leung J.C., and Lai K.N. Novel mechanisms of tubulointerstitial injury in IgA nephropathy: a new therapeutic paradigm in the prevention of progressive renal failure. Clin. Exp. Nephrol. 8 (2004) 297-303
4. Sarafidis P.A., and Bakris G.L. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 70 (2006) 1223-1233
5. Xiao J., Leung J.C., Chan L.Y., Guo H., and Lai K.N. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy. Nephrol. Dial. Transplant. (2009 Jan 20.) [Electronic publication ahead of print]
6. Sugawara A., Takeuchi K., Uruno A., Ikeda Y., Arima S., Kudo M., Sato K., Taniyama Y., and Ito S. Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142 (2001) 3125-3134
7. Lai K.N., Tang S.C., Guh J.Y., Chuang T.D., Lam M.F., Chan L.Y., Tsang A.W., and Leung J.C. Polymeric IgA1 from patients with IgA nephropathy upregulates transforming growth factor-beta synthesis and signal transduction in human mesangial cells via the renin-angiotensin system. J. Am. Soc. Nephrol. 14 (2003) 3127-3137
8. Leung J.C., Chan L.Y., Tang S.C., Tam P.C., Fenn J., and Lai K.N. Glycosylation profile of differently charged IgA1 and their binding characteristics to cultured mesangial cells in IgA nephropathy. Nephron, Exp. Nephrol. 107 (2007) e107-18
9. Tang S., Leung J.C., Abe K., Chan K.W., Chan L.Y., Chan T.M., and Lai K.N. Albumin stimulates interleukin-8 expression in proximal tubular epithelial cells in vitro and in vivo. J. Clin. Invest. 111 (2003) 515-527
10. Chan L.Y., Leung J.C., Tsang A.W., Tang S.C., and Lai K.N. Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int. 67 (2005) 602-612
11. Ruiz-Ortega M., Ruperez M., Esteban V., Rodriguez-Vita J., Sanchez-Lopez E., Carvajal G., and Egido J. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol. Dial. Transplant. 21 (2006) 16-20
12. Ballardie F.W. Quantitative appraisal of treatment options for IgA nephropathy. J. Am. Soc. Nephrol. 18 (2007) 2806-2809
13. Tontonoz P., and Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77 (2008) 289-312
14. Werman A., Hollenberg A., Solanes G., Bjorbaek C., Vidal-Puig A.J., and Flier J.S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J. Biol. Chem. 272 (1997) 20230-20235
15. Xiong Z., Huang H., Li J., Guan Y., and Wang H. Anti-inflammatory effect of PPARgamma in cultured human mesangial cells. Ren. Fail 26 (2004) 497-505
16. Maeda A., Horikoshi S., Gohda T., Tsuge T., Maeda K., and Tomino Y. Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma. Cell Biol. Int. 29 (2005) 422-428
17. Routh R.E., Johnson J.H., and McCarthy K.J. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int. 61 (2002) 1365-1376
18. Panchapakesan U., Sumual S., Pollock C.A., and Chen X. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am. J. Physiol., Renal. Physiol. 289 (2005) F1153-F1158
19. Sommer M., and Wolf G. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide. Am. J. Nephrol. 27 (2007) 425-434
20. Tang S.C., Leung J.C., Chan L.Y., Tsang A.W., and Lai K.N. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist. J. Am. Soc. Nephrol. 17 (2006) 1633-1643
21. Ko G.J., Kang Y.S., Han S.Y., Lee M.H., Song H.K., Han K.H., Kim H.K., Han J.Y., and Cha D.R. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol. Dial. Transplant. (2008)
22. Miyazaki Y., Cersosimo E., Triplitt C., and DeFronzo R.A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int. 72 (2007) 1367-1373
23. Kanjanabuch T., Ma L.J., Chen J., Pozzi A., Guan Y., Mundel P., and Fogo A.B. PPAR-gamma agonist protects podocytes from injury. Kidney Int. 71 (2007) 1232-1239
24. Benigni A., Zoja C., Tomasoni S., Campana M., Corna D., Zanchi C., Gagliardini E., Garofano E., Rottoli D., Ito T., and Remuzzi G. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J. Am. Soc. Nephrol. 17 (2006) 1624-1632
25. Yao Q., Ayala E.R., Qian J.Q., Stenvinkel P., Axelsson J., and Lindholm B. A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells. Clin. Nephrol. 68 (2007) 295-301
26. Peredo H.A., Mayer M.A., Carranza A., and Puyo A.M. Pioglitazone and losartan modify hemodynamic and metabolic parameters and vascular prostanoids in fructose-overloaded rats. Clin. Exp. Hypertens. 30 (2008) 159-169
27. Nakamura T., Yamamoto E., Kataoka K., Yamashita T., Tokutomi Y., Dong Y.F., Matsuba S., Ogawa H., and Kim-Mitsuyama S. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 51 (2008) 296-301
28. Leung J.C., Tang S.C., Chan L.Y., Chan W.L., and Lai K.N. Synthesis of TNF-alpha by mesangial cells cultured with polymeric anionic IgA-role of MAPK and NF-kappaB. Nephrol. Dial. Transplant. 23 (2008) 72-81
29. Gomez-Guerrero C., Lopez-Franco O., Suzuki Y., Sanjuan G., Hernandez-Vargas P., Blanco J., and Egido J. Nitric oxide production in renal cells by immune complexes: role of kinases and nuclear factor-kappaB. Kidney Int. 62 (2002) 2022-2034
30. Zahradka P., Werner J.P., Buhay S., Litchie B., Helwer G., and Thomas S. NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J. Mol. Cell. Cardiol. 34 (2002) 1609-1621
31. Li X.C., Carretero O.A., and Zhuo J.L. Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangial cells. Biochem. Pharmacol. 71 (2006) 1711-1719
32. Esteban V., Ruperez M., Vita J.R., Lopez E.S., Mezzano S., Plaza J.J., Egido J., and Ruiz-Ortega M. Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Inter., Suppl. (2003) S33-S38
33. Flannery P.J., and Spurney R.F. Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. Nephron, Exp. Nephrol. 103 (2006) e109-18
34. Burns K.A., and Vanden Heuvel J.P. Modulation of PPAR activity via phosphorylation. Biochim. Biophys. Acta 1771 (2007) 952-960
35. Takeda K., Ichiki T., Tokunou T., Iino N., and Takeshita A. 15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells. J. Biol. Chem. 276 (2001) 48950-48955
36. Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M., and Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor gamma. Mol. Cell. Biol. 27 (2007) 803-817
37. Burgermeister E., and Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. Cell Cycle 6 (2007) 1539-1548
38. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res. 94 (2004) 1168-1178
39. Burgermeister E., and Seger R. PPARgamma and MEK interactions in cancer. PPAR Res. 2008 (2008) 309469
40. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 (2001) 48-52
41. Efrati S., Berman S., Ilgiyeav E., Averbukh Z., and Weissgarten J. PPAR-gamma activation inhibits angiotensin II synthesis, apoptosis, and proliferation of mesangial cells from spontaneously hypertensive rats. Nephron, Exp. Nephrol. 106 (2007) e107-12
42. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., and Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol., Renal. Physiol. 292 (2007) F1141-F1150
43. Schupp M., Lee L.D., Frost N., Umbreen S., Schmidt B., Unger T., and Kintscher U. Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 47 (2006) 586-589